Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor
O. Rick et al., Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor, ANN ONCOL, 12(8), 2001, pp. 1151-1155
Background: We assessed the efficacy of amifostine for protection from chem
otherapy-induced toxicities in patients treated with conventional-dose pacl
itaxel, ifosfamide, cisplatin (TIP) and high-dose carboplatin, etoposide an
d thiotepa (CET) followed by peripheral blood progenitor cell (PBPC) rescue
.
Patients and methods: In a prospective single-center study 40 patients with
relapsed or refractory germ-cell tumors (GCT) were treated with 3 cycles o
f conventional-dose TIP followed by one cycle of high-dose CET. Patients we
re randomized either to receive one fixed dose of 500 mg amifostine per day
of conventional-dose TIP and two fixed doses of 500 mg per day amifostine
during high-dose CET (group A, n = 20) or no amifostine (group B, n = 20).
Prior to the first cycle of TIP, one course of 175 mg/m(2) paclitaxel and 5
g/m(2) ifosfamide (TI) followed by granulocyte-colony stimulating factor (
G-CSF) at 10 mug/kg/day were given for PBPC mobilization.
Results: Toxicities and response to conventional-dose TIP and high-dose CET
could be evaluated in 40 patients (100%) and 32 of 40 patients (80%), resp
ectively. Peripheral neurotoxicity (i.e. paresthesia or sensorymotor impair
ment), hearing impairment, hematologic toxicity, nephrotoxicity, nausea, my
algia, skin- and liver-toxicity did not differ siginificantly between the t
wo patient groups. Likewise, the response rates to TIP and high-dose CET we
re comparable in patients with or without amifostine. After a median follow
-up of 18 months, 8 of 20 (40%) patients of group A and 6 of 20 (30%) patie
nts of group B are without relapse.
Conclusion: Repeated low doses of 500 mg amifostine additional to conventio
nal-dose TIP or high-dose CET showed no unequivocal advantage in protection
from treatment-related toxicities. Furthermore, no significant differences
in response rates or survival could be observed in this small number of pa
tients.